These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 23790467)
1. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I. Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467 [TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954 [TBL] [Abstract][Full Text] [Related]
3. Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor. Chalret du Rieu Q; Fouliard S; Jacquet-Bescond A; Robert R; Kloos I; Depil S; Chatelut E; Chenel M Pharm Res; 2013 Oct; 30(10):2640-53. PubMed ID: 23737346 [TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Morschhauser F; Terriou L; Coiffier B; Bachy E; Varga A; Kloos I; Lelièvre H; Sarry AL; Depil S; Ribrag V Invest New Drugs; 2015 Apr; 33(2):423-31. PubMed ID: 25600050 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients. Chalret du Rieu Q; Fouliard S; White-Koning M; Kloos I; Chatelut E; Chenel M Invest New Drugs; 2014 Oct; 32(5):985-94. PubMed ID: 24875134 [TBL] [Abstract][Full Text] [Related]
6. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861 [TBL] [Abstract][Full Text] [Related]
7. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Evens AM; Balasubramanian S; Vose JM; Harb W; Gordon LI; Langdon R; Sprague J; Sirisawad M; Mani C; Yue J; Luan Y; Horton S; Graef T; Bartlett NL Clin Cancer Res; 2016 Mar; 22(5):1059-66. PubMed ID: 26482040 [TBL] [Abstract][Full Text] [Related]
8. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066 [TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Vey N; Prebet T; Thalamas C; Charbonnier A; Rey J; Kloos I; Liu E; Luan Y; Vezan R; Graef T; Recher C Leuk Lymphoma; 2017 Aug; 58(8):1880-1886. PubMed ID: 27911138 [TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766 [TBL] [Abstract][Full Text] [Related]
11. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373 [TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631 [TBL] [Abstract][Full Text] [Related]
13. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies. Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Ribrag V; Kim WS; Bouabdallah R; Lim ST; Coiffier B; Illes A; Lemieux B; Dyer MJS; Offner F; Felloussi Z; Kloos I; Luan Y; Vezan R; Graef T; Morschhauser F Haematologica; 2017 May; 102(5):903-909. PubMed ID: 28126962 [TBL] [Abstract][Full Text] [Related]
15. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467 [TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Doi T; Hamaguchi T; Shirao K; Chin K; Hatake K; Noguchi K; Otsuki T; Mehta A; Ohtsu A Int J Clin Oncol; 2013 Feb; 18(1):87-95. PubMed ID: 22234637 [TBL] [Abstract][Full Text] [Related]
18. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660 [TBL] [Abstract][Full Text] [Related]
19. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375 [TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]